457114 05			* a	etna [™]
	ETTER HEALTH®			
Coverage	Policy/Guideline			
Name:	Ebglyss (lebriki	zumab-lbkz)	Page:	1 of 8
Effective [Date: 5/23/2025		Last Review Date:	4/2025
A !:	☐ Illinois	□ Florida	⊠ New √	Jersey
Applies to:		⊠ Florida Kids	⊠ Penns	sylvania Kids
ιο.	☐ Michigan	□ Virginia	⊠ KY PF	RMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Eblgyss under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Ebglyss is indicated for the treatment of adults and pediatric patients aged 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Ebglyss can be used with or without topical corticosteroids.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Eblgyss

Policy/Guideline:

Documentation

Note: Requests require that the patient is unable to take Dupixent and Rinvoq for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

Submission of the following information is necessary to initiate the prior authorization review:

Initial requests:

- Chart notes or medical records showing affected area(s) and body surface area (where applicable).
- Chart notes or medical record documentation and claims history of prerequisite
 therapies (including topical calcineurin inhibitors, topical corticosteroids, or
 biologics/targeted synthetic drugs) including dosage, duration, and response to
 therapy. If prerequisite therapy is not advisable, documentation of why topical
 corticosteroid and/or topical calcineurin inhibitor is/are not advisable for the
 member.

AETNA BE	TTER HEALTH®		♦ a	etna
Coverage	Policy/Guideline			
Name:	Ebglyss (lebriki	zumab-lbkz)	Page:	2 of 8
Effective D	Date: 5/23/2025		Last Review Date	: 4/2025
Applica	☐ Illinois	□ Florida	⊠ New	Jersey
Applies to:			⊠ Penn	sylvania Kids
10.	☐ Michigan	□ Virginia	⊠ KY P	RMD

Continuation requests:

 Documentation (e.g., chart notes) that the member has experienced a positive clinical response to therapy as evidenced by low disease activity or improvement in signs or symptoms of atopic dermatitis.

Prescriber Specialty

This medication must be prescribed by or in consultation with a dermatologist or allergist/immunologist.

Coverage Criteria

Atopic dermatitis

Authorization of 4 months may be granted for members 12 years of age or older weighing at least 40 kg who have previously received a biologic (e.g., Dupixent) or targeted synthetic drug (e.g., Cibinqo, Rinvoq) indicated for moderate-to-severe atopic dermatitis in the past 180 days.

Authorization of 4 months may be granted for members 12 years of age or older weighing at least 40 kg for treatment of moderate-to-severe atopic dermatitis when both of the following criteria are met:

- Affected body surface is greater than or equal to 10% body surface area OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected.
- Member meets either of the following:
 - Member has had an inadequate treatment response with either of the following in the past 180 days:
 - A high potency or super-high potency topical corticosteroid (see Appendix)
 - A topical calcineurin inhibitor
 - A topical JAK inhibitor
 - A topical PDE-4 inhibitor
 - The use of high potency or super-high potency topical corticosteroid and topical calcineurin inhibitor are not advisable for the member (e.g., due to contraindications, prior intolerances, potency not appropriate for member's age).

	TTER HEALTH® Policy/Guideline		*ac	etna [™]
Name:	Ebglyss (lebrikiz	rumab-lbkz)	Page:	3 of 8
Effective D	Date: 5/23/2025		Last Review Date:	4/2025
Applica	☐ Illinois	□ Florida	⊠ New J	ersey
Applies to:		⊠ Florida Kids	⊠ Penns	ylvania Kids
10.	☐ Michigan	□ Virginia	⋈ KY PRI	MD

Continuation of Therapy

Authorization of 12 months may be granted for members 12 years of age or older (including new members) weighing at least 40 kg who are using the requested medication for moderate-to-severe atopic dermatitis when the member has achieved or maintained a positive clinical response as evidenced by low disease activity (i.e., clear or almost clear skin), or improvement in signs and symptoms of atopic dermatitis (e.g., redness, itching, oozing/crusting).

Other

Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

Dosage and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Appendix

Table. Relative potency of select topical corticosteroid products

Potency	Drug	Dosage form	Strength
I.Super-high potency (group 1)	Augmented betamethasone dipropionate	Ointment, Lotion, Gel	0.05%
I.Super-high potency (group 1)	Clobetasol propionate	Cream, Gel, Ointment, Solution, Cream (emollient), Lotion, Shampoo, Foam, Spray	0.05%
I.Super-high potency (group 1)	Fluocinonide	Cream	0.1%
I.Super-high potency (group 1)	Flurandrenolide	Tape	4 mcg/cm ²
I.Super-high potency (group 1)	Halobetasol propionate	Cream, Lotion, Ointment, Foam	0.05%
II.High potency (group 2)	Amcinonide	Ointment	0.1%

	TTER HEALTH®		* a	etna [™]
Coverage	Policy/Guideline			
Name:	Ebglyss (lebrikiz	zumab-lbkz)	Page:	4 of 8
Effective D	Date: 5/23/2025		Last Review Date:	4/2025
Amplina	☐ Illinois	□ Florida	⊠ New J	lersey
Applies to:		⊠ Florida Kids	⊠ Penns	sylvania Kids
10.	☐ Michigan	□ Virginia	⊠ KY PR	MD

II.High potency (group 2)	Potency	Drug	Dosage form	Strength
dipropionate Differency (group 2) Betamethasone dipropionate Cream D.025%	II.High potency	Augmented	Cream	0.05%
II.High potency (group 2) dipropionate Cream O.05% II.High potency (group 2) II.High potency (group 3) III.High potency (group 3) I	(group 2)	betamethasone		
(group 2) dipropionate II.High potency (group 2) Clobetasol propionate Cream 0.025% III.High potency (group 2) Desoximetasone Cream, Ointment, Spray 0.25% III.High potency (group 2) Desoximetasone Gel 0.05% III.High potency (group 2) Diflorasone diacetate Ointment, Cream (emollient) 0.05% III.High potency (group 2) Fluocinonide Cream, Ointment, Gel, Solution 0.05% III.High potency (group 2) Halcinonide Cream, Ointment 0.1% III.High potency (group 2) Halobetasol propionate Lotion 0.01% III.High potency (group 3) Amcinonide Cream, Lotion 0.1% III.High potency (group 3) Betamethasone Cream, hydrophilic emollient 0.05% III.High potency (group 3) Betamethasone valerate Ointment 0.1% III.High potency (group 3) Desoximetasone Cream, Ointment 0.05% III.High potency (group 3) Desoximetasone Cream, Ointment 0.05% III.High potency (group 3) Fluocinonide Cream, aqueous emollient 0.05% III.High potency (group 3) Fluocinonide Cream, aqueous emollient 0.05%		dipropionate		
II.High potency (group 2) III.High potency (group 2) III.High potency (group 3) III.High potency (group 5) III.High potency (group 6) III.High potency (group 7) II	II.High potency	Betamethasone	Ointment	0.05%
(group 2) II.High potency (group 3) III.High potency	(group 2)	dipropionate		
II.High potency (group 2) III.High potency (group 2) III.High potency (group 3) III.High potency (group 3)	II.High potency	Clobetasol propionate	Cream	0.025%
(group 2) II.High potency (group 2) III.High potency (group 2) III.High potency (group 3) III.High pote				
II.High potency (group 2) III.High potency (group 3) III.High potency (group 3	• •	Desoximetasone	Cream, Ointment, Spray	0.25%
(group 2) II.High potency (group 3) III.High potency (group 5) III.High potency (group 6) III.High potency (group 7) III.High pot				
II.High potency (group 2) Diflorasone diacetate Ointment, Cream (emollient) II.High potency (group 2) Fluocinonide Cream, Ointment, Gel, Solution II.High potency (group 2) Halcinonide Cream, Ointment III.High potency (group 2) III.High potency (group 2) III.High potency (group 3) III.High potency (group 3) III.High potency (group 3) Fluocinonide Cream, aqueous emollient Cream, aqueous emollient O.05% Cream, aqueous emollient O.005% Cream, aqueou	• •	Desoximetasone	Gel	0.05%
(group 2)(emollient)II.High potency (group 2)FluocinonideCream, Ointment, Gel, Solution0.05%II.High potency (group 2)HalcinonideCream, Ointment0.1%III.High potency (group 2)Halobetasol propionateLotion0.01%III.High potency (group 3)AmcinonideCream, Lotion0.1%III.High potency (group 3)Betamethasone dipropionateCream, hydrophilic emollient0.05%III.High potency (group 3)Betamethasone valerateOintment0.1%III.High potency (group 3)Betamethasone valerateFoam0.12%III.High potency (group 3)DesoximetasoneCream, Ointment0.05%III.High potency (group 3)Diflorasone diacetateCream0.05%III.High potency (group 3)FluocinonideCream, aqueous emollient0.05%III.High potency (group 3)FluocinonideCream, aqueous emollient0.05%				
II.High potency (group 2)	_	Diflorasone diacetate	·	0.05%
II.High potency (group 2)			,	
II.High potency (group 2)	• .	Fluocinonide		0.05%
II.High potency (group 2)				
II.High potency (group 2)	• .	Halcinonide	Cream, Ointment	0.1%
III.High potency (group 3) Cream, Lotion O.1% III.High potency (group 3) Betamethasone (group 3) dipropionate emollient O.1% III.High potency (group 3) Betamethasone valerate Ointment O.1% III.High potency (group 3) Betamethasone valerate Foam O.12% III.High potency (group 3) III.High potency (group 3) III.High potency (group 3) III.High potency (group 3) III.High potency (group 3) III.High potency (group 3) Cream, Ointment O.05% III.High potency (group 3) III.High potency (group 4) III.High potency (group 5) III.High potency (group 6) III.High potency (group 7) III.High pote				
III.High potency (group 3)	• .	Halobetasol propionate	Lotion	0.01%
(group 3)Betamethasone (group 3)Cream, hydrophilic emollient0.05%III. High potency (group 3)Betamethasone valerate (group 3)Ointment0.1%III. High potency (group 3)Betamethasone valerateFoam0.12%III. High potency (group 3)DesoximetasoneCream, Ointment0.05%III. High potency (group 3)Diflorasone diacetate (group 3)Cream0.05%III. High potency (group 3)FluocinonideCream, aqueous emollient 				0.107
III.High potency (group 3) III.High potency Fluocinonide (group 3) III.High potency Fluicasone propionate (group 3) III.High potency Fluicasone propionate (group 3)	• .	Amcinonide	Cream, Lotion	0.1%
(group 3)dipropionateemollientIII.High potency (group 3)Betamethasone valerateOintment0.1%III.High potency (group 3)Betamethasone valerateFoam0.12%III.High potency (group 3)DesoximetasoneCream, Ointment0.05%III.High potency (group 3)Diflorasone diacetateCream0.05%III.High potency (group 3)FluocinonideCream, aqueous emollient0.05%III.High potency (group 3)Fluticasone propionateOintment0.005%		Determently	Our and hardwardsilia	0.050/
III.High potency (group 3) III.High potency Fluocinonide III.High potency (group 3)	• .		· · · · · · · · · · · · · · · · · · ·	0.05%
(group 3)Betamethasone valerateFoam0.12%(group 3)DesoximetasoneCream, Ointment0.05%(group 3)Diflorasone diacetateCream0.05%(group 3)Cream, aqueous emollient0.05%(group 3)FluocinonideCream, aqueous emollient0.05%(group 3)FluocinonideCream, aqueous emollient0.05%(group 3)FluocinonideCream, aqueous emollient0.05%				0.10/
III.High potency (group 3) III.High potency Flucionate	• .	Betamethasone vaterate	Ointment	0.1%
(group 3)DesoximetasoneCream, Ointment0.05%(group 3)Diflorasone diacetateCream0.05%(group 3)Diflorasone diacetateCream0.05%(group 3)FluocinonideCream, aqueous emollient0.05%(group 3)FluocinonideOintment0.005%	•	Potomothosono voloroto	Foom	0.129/
III.High potency (group 3) III.High potency Fluciasone propionate Ointment O.05% O.05%		Detainethasone vaterate	Toam	0.1276
(group 3)Diflorasone diacetateCream0.05%(group 3)Cream, aqueous emollient0.05%III.High potency (group 3)Cream, aqueous emollient0.05%III.High potencyFluticasone propionateOintment0.005%	•	Desovimetasone	Cream Cintment	0.05%
III.High potency (group 3) III.High potency (group 3) III.High potency (group 3) III.High potency (group 3) III.High potency Fluticasone propionate O.05% O.05% O.005%		Desoximetasone	Gream, Giritment	0.0070
(group 3)Cream, aqueous emollient0.05%(group 3)Cream, aqueous emollient0.05%III.High potencyFluticasone propionateOintment0.005%	III High potency	Diflorasone diacetate	Cream	0.05%
III.High potency (group 3) III.High potency Fluocinonide Cream, aqueous emollient 0.05% Ontment 0.005%	• .	2	3.34.11	3.5575
(group 3) III.High potency Fluticasone propionate Ointment 0.005%		Fluocinonide	Cream, aqueous emollient	0.05%
III.High potency Fluticasone propionate Ointment 0.005%	• .		2. 25, 2.42.2000 00000	
		Fluticasone propionate	Ointment	0.005%
	(group 3)	1		
III.High potency Mometasone furoate Ointment 0.1%	•	Mometasone furoate	Ointment	0.1%
(group 3)	• .			

AETNA BE	TTER HEALTH®		*ae	etna
Coverage	Policy/Guideline			
Name:	Ebglyss (lebrikiz	zumab-lbkz)	Page:	5 of 8
Effective D	Date: 5/23/2025		Last Review Date:	4/2025
Amplina	☐ Illinois	□ Florida	⊠ New Je	ersey
Applies to:		⊠ Florida Kids	⊠ Pennsy	/lvania Kids
10.	☐ Michigan	□ Virginia	⊠ KY PRI	MD

Potency	Drug	Dosage form	Strength
III.High potency	Triamcinolone acetonide	Cream, Ointment	0.5%
(group 3)	Thancinolone acetonide	Cream, Omment	0.5%
IV.Medium	Betamethasone	Spray	0.05%
potency (group	dipropionate		
4)			
IV.Medium	Clocortolone pivalate	Cream	0.1%
potency (group			
4)			
IV.Medium	Fluocinolone acetonide	Ointment	0.025%
potency (group			
4)	Elemental de	Ointen and	
IV.Medium	Flurandrenolide	Ointment	0.05%
potency (group 4)			0.05%
IV.Medium	Hydrocortisone valerate	Ointment	0.2%
potency (group	Tryarocordsone valorate	- Ciritatione	0.270
4)			
IV.Medium	Mometasone furoate	Cream, Lotion, Solution	0.1%
potency (group			
4)			
IV.Medium	Triamcinolone acetonide	Cream	0.1%
potency (group			
4)			
IV.Medium	Triamcinolone acetonide	Ointment	0.05% and
potency (group			0.1%
4)			
IV.Medium	Triamcinolone acetonide	Aerosol Spray	0.2 mg per 2-
potency (group			second spray
4) V.Lower-mid	Betamethasone	Lotion	0.05%
potency (group	dipropionate	Lotion	0.05%
5)	αιριορισταίε		
V.Lower-mid	Betamethasone valerate	Cream	0.1%
potency (group			
5)			
V.Lower-mid	Desonide	Ointment, Gel	0.05%
potency (group			
5)			

	TTER HEALTH® Policy/Guideline		*a 6	etna [™]
Name:	Ebglyss (lebrikiz	rumab-lbkz)	Page:	6 of 8
Effective D	Date: 5/23/2025		Last Review Date:	4/2025
Applica	☐ Illinois	□ Florida	⊠ New J	ersey
Applies to:		⊠ Florida Kids	⊠ Penns	ylvania Kids
10.	☐ Michigan	□ Virginia	⋈ KY PR	MD

Potency	Drug	Dosage form	Strength
V.Lower-mid potency (group 5)	Fluocinolone acetonide	Cream	0.025%
V.Lower-mid potency (group 5)	Flurandrenolide	Cream, Lotion	0.05%
V.Lower-mid potency (group 5)	Fluticasone propionate	Cream, Lotion	0.05%
V.Lower-mid potency (group 5)	Hydrocortisone butyrate	Cream, Lotion, Ointment, Solution	0.1%
V.Lower-mid potency (group 5)	Hydrocortisone probutate	Cream	0.1%
V.Lower-mid potency (group 5)	Hydrocortisone valerate	Cream	0.2%
V.Lower-mid potency (group 5)	Prednicarbate	Cream (emollient), Ointment	0.1%
V.Lower-mid potency (group 5)	Triamcinolone acetonide	Lotion	0.1%
V.Lower-mid potency (group 5)	Triamcinolone acetonide	Ointment	0.025%
VI.Low potency (group 6)	Alclometasone dipropionate	Cream, Ointment	0.05%
VI.Low potency (group 6)	Betamethasone valerate	Lotion	0.1%
VI.Low potency (group 6)	Desonide	Cream, Lotion, Foam	0.05%
VI.Low potency (group 6)	Fluocinolone acetonide	Cream, Solution, Shampoo, Oil	0.01%
VI.Low potency (group 6)	Triamcinolone acetonide	Cream, lotion	0.025%

	TTER HEALTH® Policy/Guideline		* a	etna™
Name:	Ebglyss (lebrik	izumab-lbkz)	Page:	7 of 8
Effective D	Date: 5/23/2025		Last Review Date	e: 4/2025
Analiaa	☐ Illinois	□ Florida	⊠ New	Jersey
Applies to:			⊠ Penr	nsylvania Kids
ιυ.	☐ Michigan	□ Virginia	⊠ KY P	RMD

Potency	Drug	Dosage form	Strength
VII. Least potent (group 7)	Hydrocortisone (base, greater than or equal to 2%)	Cream, Ointment, Solution	2.5%
VII. Least potent (group 7)	Hydrocortisone (base, greater than or equal to 2%)	Lotion	2%
VII. Least potent (group 7)	Hydrocortisone (base, less than 2%)	Cream, Ointment, Gel, Lotion, Spray, Solution	1%
VII. Least potent (group 7)	Hydrocortisone (base, less than 2%)	Cream, Ointment	0.5%
VII. Least potent (group 7)	Hydrocortisone acetate	Cream	2.5%
VII. Least potent (group 7)	Hydrocortisone acetate	Lotion	2%
VII. Least potent (group 7)	Hydrocortisone acetate	Cream	1%

Approval Duration and Quantity Restrictions:

Initial Approval: 4 months
Renewal Approval: 12 months

Quantity Level Limits:

- 2 syringes/pens every 30 days
- Exception limit: 4 syringes/pens per 15 days

References:

- 1. Ebglyss [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2024.
- 2. Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023;388(12):1080-1091.
- 3. Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023;159(2):182-191.

			* a	etna [®]
AETNA BETTER HEALTH®				
Coverage	Policy/Guideline			
Name:	ne: Ebglyss (lebrikizumab-lbkz)		Page:	8 of 8
Effective Date: 5/23/2025			Last Review Date	: 4/2025
Applies to:	☐ Illinois	□ Florida		
		⊠ Florida Kids	🛛 Pennsylvania Kids	
	☐ Michigan	□ Virginia	⋈ KY PRMD	

- 4. Eichenfield LF, Tom WL, Chamlin SL, et. al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and Assessment of Atopic Dermatitis. J Am Acad Dermatol. 2014;70:338-351.
- 5. Sidbury R, Alikhan A, Bercovitch L, et. al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20.
- 6. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024 Feb;90(2):e43-e56.
- 7. Topical Corticosteroids. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health Inc; July 18, 2024. Accessed November 9, 2024.